Who are Losartan/Chlorthalidone in fixed dose's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/losartan-chlorthalidone-in-fixed-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Losartan/Chlorthalidone in fixed dose — Competitive Intelligence Brief

Losartan/Chlorthalidone in fixed dose (Losartan/Chlorthalidone in fixed dose) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor antagonist + thiazide-like diuretic combination. Area: Cardiovascular.

phase 3 Angiotensin II receptor antagonist + thiazide-like diuretic combination Angiotensin II type 1 (AT1) receptor; sodium-chloride cotransporter Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Losartan/Chlorthalidone in fixed dose (Losartan/Chlorthalidone in fixed dose) — Laboratorios Silanes S.A. de C.V.. Losartan blocks angiotensin II receptors to lower blood pressure, while chlorthalidone is a thiazide-like diuretic that reduces fluid volume and sodium reabsorption.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Losartan/Chlorthalidone in fixed dose TARGET	Losartan/Chlorthalidone in fixed dose	Laboratorios Silanes S.A. de C.V.	phase 3	Angiotensin II receptor antagonist + thiazide-like diuretic combination	Angiotensin II type 1 (AT1) receptor; sodium-chloride cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor antagonist + thiazide-like diuretic combination class)

Laboratorios Silanes S.A. de C.V. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Losartan/Chlorthalidone in fixed dose — Competitive Intelligence Brief. https://druglandscape.com/ci/losartan-chlorthalidone-in-fixed-dose. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab